News Archives

Rodos Biotarget Receives Government Funding for Developing Antibiotic-loaded Nanocarriers

Three-year funding of EUR 2.8 million for top-tier research consortium by Germany’s BMBF. Towards advancing targeted drug application to manage treatment-resistant pathogens  Hannover, Germany, 16 October 2017. In recent years, antibiotic resistances of bacterial pathogens have reached a threatening dimension

Posted in Press

A Message of Thanks to All Our Backers

You have donated a grand total of $7,035, 156% of our funding goal. Your generous support has enabled the studies to begin in two weeks when we start the process of testing our hypothesis: Can Effective Targeted Delivery of Curcumin

Posted in News

Louis Capozzi Receives PRSAs Gold Anvil Award for Lifetime Achievement in Public Relations

NEW YORK (Oct. 8, 2017) — The Public Relations Society of America (PRSA) presented Louis Capozzi, APR, Fellow PRSA, with its Gold Anvil Award, the Society’s highest individual award and considered to be the Society’s lifetime achievement award. The award was presented at

Posted in Press

Science Crowdfunding Campaign Exceeds Funding Goal

We are very pleased to report success in pledges of $6448 from the public at a Science Crowdfunding Platform. This is 143% of our original funding goal of $4500, permitting us to begin a preclinical Proof of Concept study in

Posted in News

Cancer Research Online Crowdsourcing Campaign Passes 78% of Funding Goal

An early-stage drug development company in South Carolina has launched an online fundraising campaign to study the ancient spice curcumin in combination with an FDA-approved Immune Checkpoint Inhibitor to fight colon cancer. Download and read the Press Release [PDF]

Posted in Press

Augustus BioTarget starting a targeted cancer treatment study this fall

Augustus BioTarget is starting a targeted cancer treatment study with curcumin encapsulated in the Rodos CLR/ TargoSphere this October in a colon cancer mouse model.

Posted in News

Crowdfunding triggers Capital Increase of 800,000 Euros at Rodos Biotarget

Hannover, 17 August 2017. Rodos Biotarget is the first German life-science company to initiate crowdfunding campaigns via two crowd platforms. In 2016, a first round took place with Seedmatch, and a current financing round is running with Hannover, 17 August

Posted in Press

Drug Development in Alzheimer’s Disease: the Path to 2025

Jeffrey Cummings, Paul S. Aisen, Bruno DuBois, Lutz Frölich, Clifford R. JackJr, Roy W. Jones, John C. Morris, Joel Raskin, Sherie A. Dowsett and Philip Scheltens From: Alzheimer’s Research & Therapy Sept. 2016; 20168:39 The global impact of Alzheimer’s disease

Posted in News

Rodos Biotarget will host ‘Future Medicine Symposium’

Augustus BioTarget is using a specialized Rodos nanocarrier to target the immune system in the development of a new treatment for Alzheimer’s disease. Hannover, Germany, 28 October 2016. A biopharmaceutical company, Rodos Biotarget joins the ranks of industry leadership in

Posted in News

We are developing an Immunotherapeutic Approach to the Treatment of Early and Mid-Stage Alzheimer Dementias

Invest in EquityNet Crowdfunding to Help Develop Our New Alzheimer Treatment: www.equitynet.com/c/augustus-biotarget-inc For more information visit the Alzheimer’s Disease Project page.

Posted in News